Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $HSDT
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/15/2021 | Outperform → Market Perform | Noble Capital Markets |
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ("BCI") Technology Private Subsidiary
--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence ("AI") Powered BCI Technology-- --Helius' existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development-- --Helius to Present at the 37th Annual ROTH Conference on Monday, March 17 at 12:00pm PT-- NEWTOWN, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for improving balance and gait deficits and reducing the risk of falling, today announced the establishment of Revelation
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
--Anthem Blue Cross Blue Shield approves claim for PoNS Device at out-of-network adjusted list price-- --Provides further validation of PoNS pricing-- NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced its first reimbursement payment from a major healthcare provider, Anthem Blue Cross Blue Shield, for its PoNS Device. "The first reimbursement from a commercial healthcare provider is a significant achievement for Helius and MS patients. The payment at out-of-network adjusted list
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study
--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1 to 5.9, p<0.001) at week 14-- NEWTOWN, Pa., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive results from the
Helius Medical Tech downgraded by Noble Capital Markets
Noble Capital Markets downgraded Helius Medical Tech from Outperform to Market Perform
Noble Capital Markets initiated coverage on Helius Medical with a new price target
Noble Capital Markets initiated coverage of Helius Medical with a rating of Outperform and set a new price target of $20.00
LADENBURG THALM/SH SH initiated coverage on Helius Medical Technologies
LADENBURG THALM/SH SH initiated coverage of Helius Medical Technologies with a rating of Buy
Andreeff Dane bought $8,229 worth of shares (1,284 units at $6.41) (SEC Form 4) (Amendment)
4/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
Andreeff Dane bought $40,475 worth of shares (5,000 units at $8.10) (SEC Form 4)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
Andreeff Dane bought $25,675 worth of shares (4,006 units at $6.41) (SEC Form 4)
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
SEC Form 4 filed by CFO and Treasurer Mathiesen Jeffrey S
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
SEC Form 4 filed by Director Perkins Sherrie L
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
SEC Form 4 filed by Chief Medical Officer Favit-Van Pelt Antonella R.
4 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)
SEC Form EFFECT filed by Helius Medical Technologies Inc.
EFFECT - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
SEC Form 424B5 filed by Helius Medical Technologies Inc.
424B5 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
SEC Form S-8 filed by Helius Medical Technologies Inc.
S-8 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)
Helius Medical Technologies, Inc. Appoints Paul Buckman to its Board of Directors
NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I
Better For You Wellness Appoints Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD to its Board of Directors
Columbus, Ohio, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Better For You Wellness, Inc., formerly known as Fast Track Solutions, Inc., (OTC:FTRK) ("Better For You Wellness" or the "Company"), an Ohio-based blank check company, is pleased to announce that it has appointed five independent non-executive directors to its Board of Directors including Montel Williams, Leslie Bumgarner, Joseph Watson, David Deming, and Dr. Nicola Finley, MD (the "New Directors"). All five New Directors have been appointed for initial terms of 2 years, and Better For You Wellness, Inc.'s seven member Board of Directors is now composed of a majority of Independent Directors demonstrating the Company's focus on governance
Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer
NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Antonella Favit-Van Pelt, M.D., Ph.D. to the position of Chief Medical Officer. "I am very pleased to welcome Dr. Favit-Van Pelt to Helius, who joins our team with a clinical and academic background in Neurology, as well as 20 years of experience advising and leading medical programs for healthcare companies – including both large, globally-diversified corporations and smaller, earlier-stage companies," said Helius CEO, Dane Andreeff. "I look forward to her future cont
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET. "We disagree with the proposed pricing for the PoNS Mouthpiece and are disappointed CMS has once again mapped the Controller pricing to a code for fundamentally different technology," said Dane Andreeff, Helius' President and Chief Executive Officer. "I
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date:Monday, Augus
Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024
NEWTOWN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2024 financial results on Monday, May 13, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius' progress and plans surrounding the U.S. commercialization of PoNS® as follows: Date: Monday, May 13, 2
Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SEC Form SC 13G filed by Helius Medical Technologies Inc.
SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)
SEC Form SC 13G/A filed by Helius Medical Technologies Inc. (Amendment)
SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)